Tyto Insights for Rhonchi Detection

The Tyto Insights for Rhonchi Detection is an AI-enabled software system designed for prescription use to assist healthcare professionals in identifying suspected rhonchi by analyzing acoustic signals from Tyto Stethoscope recordings. Its methodology involves an AI model that processes lung sound data, which has been clinically validated to be non-inferior to human readers, enabling its use as a Class II medical product.

On April 7, 2025, Tyto Care Ltd. received a determination from the U.S. Food & Drug Administration concerning their product, Tyto Insights for Rhonchi Detection. This artificial intelligence (AI)-enabled software system is intended for prescription use, aiding in the evaluation of lung sounds in adults and pediatric patients aged two years and older. It automatically analyzes acoustic signals from compatible Tyto Stethoscope recordings to identify the suspected presence of "Rhonchi," an abnormal lung sound. The system's output is designed to be interpreted by a licensed healthcare professional, who must integrate the results with other patient data.Following a comprehensive review, the product was deemed substantially equivalent to a previously marketed device, enabling its availability for market. Classified as a Class II medical product, it is subject to standard regulatory oversight, including requirements for annual registration, product listing, and adherence to good manufacturing practices. A Predetermined Change Control Plan was also reviewed and accepted, allowing certain software modifications—such as re-training the AI model or incorporating new compatible input sources—without requiring a new review, provided these changes do not significantly impact safety or effectiveness. Clinical validation studies confirmed the device's performance in detecting rhonchi, establishing its non-inferiority compared to clinical readers, and supporting its safety and effectiveness for its intended application.

AI Regulatory Concerns

Powered by

Jev reads the full FDA letter and returns calibrated concern probabilities per regulatory category. These are AI estimates, not regulatory advice.

• Q1. What were the specific sensitivity and specificity results from the clinical validation studies that supported the device's non-inferiority?; How does the AI model differentiate rhonchi from other similar lung sounds, and what are its known limitations in complex or atypical cases?; What types of additional patient data are crucial for healthcare professionals to integrate with the Tyto Insights output to ensure accurate clinical interpretation?; What specific criteria or thresholds will be used under the Predetermined Change Control Plan to determine if software modifications significantly impact safety or effectiveness, thus requiring new FDA review?; Are there plans to expand the Tyto Insights system to detect other specific abnormal lung sounds beyond rhonchi, or to incorporate additional diagnostic parameters?